Juvenile Arthritis News

Rheumatologists opt for therapy regimens that include rituximab more often than nephrologists in treating refractory lupus nephritis or renal flare in children, according to data published in Pediatric Rheumatology.

Living under COVID-19 lockdown was associated with a higher rate of joint inflammation in children with juvenile idiopathic arthritis, according to data from an Italian cohort published in Arthritis Care & Research.

There is significant variation in the patterns of methotrexate use prior to initiating etanercept in patients with juvenile idiopathic arthritis, according to registry data published in Pediatric Rheumatology.

Male patients diagnosed with inflammatory arthritis at or before peak reproductive age have a lower fertility rate, a higher childlessness rate, and more fertility issues, according to data published in the Annals of the Rheumatic Diseases.

In children who present to the pediatric ED, a point-of-care ultrasonography decision-support algorithm — a rule-in tool — accurately diagnosed transient synovitis, according to data published in JAMA Network Open.

This past spring, two studies shed light on how some of the largest clinician organizations and publishers in rheumatology, including the American College of Rheumatology and EULAR, have failed to provide adequate training materials or clear guidelines when it comes to caring for patients of color.

Biologic initiation in children hospitalized with new-onset systemic juvenile idiopathic arthritis increased significantly from 2008 to 2019, reaching 40% between 2017 and 2019, and may be linked with reduced glucocorticoid use, according to data.

Nearly 66% of pediatric rheumatology providers reported that telehealth visits were inadequate for complete clinical assessments, while 35.8% found their level of burnout had increased due to telehealth, according to survey results.

Three strategies aimed at starting patients with polyarticular juvenile idiopathic arthritis on different combinations of DMARDs and biologics resulted in similar rates of clinically inactive disease without glucocorticoids at 12 months, according to data.

On May 11, Icelandic-based drug developer Alvotech filed a lawsuit against AbbVie seeking to undo what it alleges is a “minefield” of “invalid” patents surrounding what is arguably the pharma giant’s most prized possession: Humira.